Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More

Singapore Clinical Trial: Using AS01 adjuvant to improve immune response in older adults through trained immunity

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'Using AS01 adjuvant to improve immune response in older adults through trained immunity'. The foll... Read More

Singapore Clinical Trial: A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability ... Read More

Singapore Clinical Trial: A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate(ADC), in Participants with Advanced HER2+ Solid Tumors

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Pre... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More

Singapore Clinical Trial: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Invest... Read More

Clinical Trial: Flow Cytometric Immune Monitoring of B. Afzelii-Specific T Lymphocytes

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07703787) titled 'Flow Cytometric Immune Monitoring of B. Afzelii-Specific T Lymphocytes' on July 09. Brief ... Read More

Singapore Clinical Trial: Regime for vitamin D maintEnanCe In poSt-operatIVE patients (D-ECISIVE) Randomized Controlled Trial

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'Regime for vitamin D maintEnanCe In poSt-operatIVE patients (D-ECISIVE) Randomized Controlled Tria... Read More

Clinical Trial: Validity and Reliability of the DeepClinic Posture Assessment Application

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07702331) titled 'Validity and Reliability of the DeepClinic Posture Assessment Application' on July 09. Bri... Read More

Singapore Clinical Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Singapore, July 15 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More

• ««
• «
• 240
• 241
• 242
• 243
• 244
• 245
• 246
• 247
• 248
• 249
• »
• »»